Trevi Therapeutics, Inc. (TRVI)
After hours:
| Previous close | 2.9800 |
| Open | 3.0300 |
| Bid | 2.8600 x 200 |
| Ask | 2.9500 x 100 |
| Day's range | 2.8500 - 3.0785 |
| 52-week range | 0.9700 - 4.0000 |
| Volume | |
| Avg. volume | 225,574 |
| Market cap | 203.557M |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3400 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.33 |
Simply Wall St.Here's Why We're Not Too Worried About Trevi Therapeutics' (NASDAQ:TRVI) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Insider MonkeyTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call Transcript
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call Transcript May 11, 2024 Trevi Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to the Trevi Therapeutics First Quarter 2024 Earnings Conference Call. At this time, […]
PR NewswireTrevi Therapeutics to Participate in Upcoming Conferences
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending investor, business development and medical conferences in May and June.
